Chemours Company (CC) AI Stock Analysis

• Market Cap: $2.25B
• Dividend Yield: 4.91%
• Average Volume (3M): 2.92M
• Price to Earnings (P/E): 59.3
• Beta (1Y): 1.91
• Revenue Growth: 2.48%
• EPS Growth: -459.90%
• Country: US
• Employees: 6,000
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 0.58
• Shares Outstanding: 149,698,300
• 10 Day Avg. Volume: 2,659,478
• 30 Day Avg. Volume: 2,917,671
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 2.50
• Enterprise Value/Revenue: 0.96
• Enterprise Value/Gross Profit: 5.24
• Enterprise Value/Ebitda: 23.74
• 1Y Price Target: $17.00
• Price Target Upside: 23.73% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 10

• Rating: 41 Neutral
• Price Target: $13.00 ▼(-5.39% Downside)

The overall stock score of 41 reflects significant financial challenges, including high leverage and negative profitability, which are the most impactful factors. Technical analysis indicates bearish momentum, further weighing on the score. While the dividend yield offers some support, valuation concerns persist due to negative earnings.

Positive Factors

Opteon Refrigerants Demand

The strong demand for Opteon Refrigerants reflects Chemours' competitive advantage in the fluoroproducts market, driven by regulatory mandates and seasonal demand. This positions the company well for sustained growth in this segment.

Settlement with New Jersey

The settlement with New Jersey resolves significant environmental claims, reducing legal uncertainties and financial liabilities, thus improving long-term financial stability and allowing Chemours to focus on core business operations.

Strategic Leadership Changes

The appointment of Mary Cranston as Chair of the Board introduces experienced leadership, potentially enhancing strategic direction and governance, which could positively impact long-term business strategy and stakeholder confidence.

Negative Factors

High Leverage

Chemours' high leverage poses a financial risk, limiting flexibility and increasing vulnerability to economic downturns, which could impact long-term operational stability and investment capacity.

Negative Cash Flow

Negative cash flow indicates challenges in cash generation, potentially hindering Chemours' ability to invest in growth opportunities and meet financial obligations, affecting long-term sustainability.

Operational Disruptions

Operational disruptions in the Titanium Technologies segment highlight issues in operational discipline, which could affect production efficiency and financial performance, posing risks to long-term competitiveness.

Chemours Company Business Overview & Revenue Model

Company Description

Chemours Company (CC) is a global leader in titanium technologies, fluoroproducts, and chemical solutions. Founded in 2015 as a spin-off from DuPont, Chemours operates in several key sectors, including titanium dioxide, fluoroproducts, and specialty chemicals. Its core products include TiO2, a pigment used in paints and coatings, as well as refrigerants, and other fluorinated products that serve various industries such as automotive, construction, and electronics.

How the Company Makes Money

Chemours generates revenue primarily through the sale of its core products across its three main segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment is a significant revenue driver, producing titanium dioxide, which is essential for a wide range of applications. The Fluoroproducts segment includes refrigerants and other fluorinated offerings, benefiting from strong demand in the HVAC and automotive markets. The Chemical Solutions segment provides performance chemicals used in various applications, contributing to diversified revenue streams. Key revenue sources also stem from long-term contracts with major customers in various industries and the company's strategic partnerships that enhance its market reach and innovation capabilities. Additionally, Chemours benefits from its investment in sustainable practices and product development, responding to the increasing market demand for environmentally friendly solutions.

Chemours Company Financial Statement Overview

Summary

Chemours Company is facing financial difficulties with declining profitability and high leverage. Despite slight revenue growth, the company struggles with negative net income and cash flow issues. High debt levels pose a risk, and operational efficiency needs improvement.

Income Statement

The income statement shows a mixed performance. The TTM (Trailing-Twelve-Months) revenue growth is slightly positive at 1.33%, but the company is facing profitability challenges with a negative net income of $420 million. Gross profit margins have declined over the years, and the EBIT and EBITDA margins are lower compared to previous periods, indicating reduced operational efficiency.

Balance Sheet

The balance sheet reveals significant leverage with a high debt-to-equity ratio of 7.57 in the TTM period, indicating potential financial risk. Stockholders' equity has decreased, and the return on equity has turned negative, reflecting the company's struggle to generate returns for shareholders. The equity ratio is also low, suggesting a heavy reliance on debt financing.

Cash Flow

Cash flow analysis indicates challenges in cash generation. The TTM free cash flow is negative, and the free cash flow growth rate has significantly declined. The operating cash flow to net income ratio is negative, highlighting inefficiencies in converting income into cash. However, the free cash flow to net income ratio is positive, suggesting some ability to generate cash relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.88B	5.78B	6.03B	6.79B	6.34B	4.97B
Gross Profit	1.07B	1.15B	1.31B	1.62B	1.38B	1.07B
EBITDA	237.00M	692.00M	197.00M	1.20B	1.21B	767.00M
Net Income	-420.00M	86.00M	-238.00M	578.00M	608.00M	219.00M
Balance Sheet
Total Assets	7.49B	7.51B	8.25B	7.64B	7.55B	7.08B
Cash, Cash Equivalents and Short-Term Investments	502.00M	713.00M	1.20B	1.10B	1.45B	1.10B
Total Debt	244.00M	4.36B	4.30B	3.81B	3.93B	4.28B
Total Liabilities	7.25B	6.91B	7.51B	6.53B	6.47B	6.27B
Stockholders Equity	237.00M	604.00M	737.00M	1.11B	1.08B	813.00M
Cash Flow
Free Cash Flow	-35.00M	-993.00M	186.00M	447.00M	543.00M	540.00M
Operating Cash Flow	277.00M	-633.00M	556.00M	754.00M	820.00M	807.00M
Investing Cash Flow	-310.00M	-353.00M	-229.00M	-284.00M	220.00M	-234.00M
Financing Cash Flow	-26.00M	-36.00M	172.00M	-685.00M	-560.00M	-449.00M

Chemours Company Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.74
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CC, the sentiment is Negative. The current price of 13.74 is below the 20-day moving average (MA) of 16.16, below the 50-day MA of 15.05, and below the 200-day MA of 14.07, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 32.02 is Neutral, neither overbought nor oversold. The STOCH value of 7.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CC.

Chemours Company Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KWR	63 Neutral	$2.30B	21.71	-0.52%	1.51%	-3.09%	-106.46%
IOSP	63 Neutral	$1.95B	104.11	1.55%	2.14%	-5.45%	-87.13%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
NGVT	61 Neutral	$1.98B	―	-106.83%	―	-14.45%	49.92%
OLN	54 Neutral	$2.94B	41.89	-0.69%	3.22%	1.49%	-105.20%
ASH	46 Neutral	$2.22B	21.03	-34.43%	3.38%	-11.38%	-690.99%
CC	41 Neutral	$2.25B	59.33	-87.50%	4.91%	2.48%	-459.90%

Chemours Company Corporate Events

Chemours Appoints New Chair and Lead Director

On September 2, 2025, Chemours Company announced changes in its Board of Directors, appointing Mary Cranston as Chair and Alister Cowan as Lead Independent Director, following Dawn Farrell’s departure to join the Canadian government. These leadership changes are significant for the company’s governance and may influence its strategic direction and stakeholder relations.

Chemours Chair Dawn Farrell Resigns for New Role

On August 29, 2025, Dawn Farrell, Chair of the Board of Directors at The Chemours Company, announced her resignation effective September 2, 2025, to take on a new role as Chief Executive Officer of the Major Projects Office under the Canadian government. The company has yet to decide on her successor, signaling a forthcoming announcement regarding the new Chair of the Board.

Chemours Agrees to $875M Settlement with New Jersey

On August 3, 2025, Chemours, Corteva, and DuPont agreed to a proposed Judicial Consent Order with the State of New Jersey to resolve all pending environmental claims, including PFAS contamination, related to their operating sites and statewide issues. The settlement involves a $875 million payment over 25 years, with Chemours responsible for 50% of the payments. The agreement also includes mechanisms for future remediation funding and establishes a Reserve Fund for financial security. Additionally, Chemours entered into an agreement to sell its rights to $150 million in insurance proceeds related to PFAS claims to DuPont and Corteva.